PlusTen Intelligence
Updating the operating model
- January 2026
A4BEE prepared this analysis from publicly available sources. It reflects our own reading of PlusTen Intelligence's published strategy and is not endorsed by, or produced in cooperation with, PlusTen Intelligence.
Strategic priorities
PlusTen Intelligence operates across 4 stated priorities, with the most concrete near-term plan anchored on biological high-fidelity signal acquisition.
Utilizing living neurons to record both electrical and chemical signals, replacing traditional electrodes with living axons to increase signal density and eliminate biocompatibility challenges that plague conventional brain-computer interfaces and organoid sensing platforms.
Pursuing smooth integration with existing laboratory ecosystems through MTP standards and vendor-agnostic protocols, avoiding proprietary "Vendor Lock-In" while ensuring compatibility with standard lab equipment for rapid adoption.
Developing programmable neurons designed to detect specific molecules, transforming the platform from passive monitoring into an active sensor for synthetic biology and personalized oncology applications with patient-specific profiling capabilities.
-
01
Biological High-Fidelity Signal Acquisition
Utilizing living neurons to record both electrical and chemical signals, replacing traditional electrodes with living axons to increase signal density and eliminate biocompatibility challenges that plague conventional brain-computer interfaces and organoid sensing platforms.
-
02
Infrastructure Democratization and Hardware Interoperability
Pursuing smooth integration with existing laboratory ecosystems through MTP standards and vendor-agnostic protocols, avoiding proprietary "Vendor Lock-In" while ensuring compatibility with standard lab equipment for rapid adoption.
-
03
Targeted Biomolecule Programming
Developing programmable neurons designed to detect specific molecules, transforming the platform from passive monitoring into an active sensor for synthetic biology and personalized oncology applications with patient-specific profiling capabilities.
-
04
Scalable Clinical Translation
Building high-throughput pipelines that enable continuous feedback and real-time adjustments from R&D through clinical translation, utilizing Digital Twin simulations to optimize yields and predict batch outcomes before physical execution.
Challenges we see
- Digital Transformation Digital
Electrophysiological Data Fragmentation and Latency
High-density signal acquisition from biological neural networks generates massive real-time data volumes that create isolated "data islands" where local processing cannot keep up with biological throughput, compounded by lack of unified IT/OT architecture.
High latency in signal processing leads to "lost in translation" data, risking incorrect conclusions in drug efficacy studies and regulatory compliance gaps with ALCOA+ principles through manual data transfers.
- Infrastructure Connectivity Technology Implementation
Legacy IT/OT Integration Complexity
Modern laboratories operate on mixed legacy equipment (Siemens S5 PLCs, RS-232, Profibus interfaces) and modern digital lines, requiring sophisticated IT/OT architecture that the company currently lacks as an unfunded startup.
Air-gapped legacy equipment creates isolated "dark data" pockets that block real-time monitoring, undermining the ROI of high-fidelity signal acquisition through manual data entry and operational blind spots.
- Human Capital Labor
Digital Hesitancy and Trust Deficit
Highly skilled scientists display "Digital Hesitancy" when transitioning from manual monitoring to AI-driven platforms, with documented "Trust Deficit" where operators fear automation algorithms will fail without transparency; 57% of staff lack technical knowledge for sophisticated software.
Risk aversion leads operators to keep systems in "Manual Mode," reverting to Excel workarounds and USB transfers, stalling adoption rates and undermining the value of advanced automation investments.
- Manufacturing & R&D Manufacturing
High-Throughput Bioprocess Instability
Scaling from pilot laboratory to industrial-scale high-throughput screening introduces biological unpredictability, with living neurons sensitive to anomalies like liquid overflows, foam spikes, and environmental fluctuations across thousands of simultaneous batches.
Without advanced PAT or Process Orchestration Layers, undetected batch failures in an unfunded startup environment can severely strain financial runway, making scale-up from 500L+ batches a high-risk endeavor.
- Regulatory Pressure Digital/Compliance
Regulatory Compliance and GxP Validation
Life Sciences operations face immense pressure for GxP compliance and 21 CFR Part 11 standards, with novel neuron-on-chip technology adding regulatory complexity; approval timelines can average 31 months, and the company relies on paper-based legacy records.
Fragmented data islands and manual capture methods increase "clock-stop" likelihood in regulatory evaluations, with 47% of delays attributed to data requests; without immutable electronic audit trails, clinical translation pathways can be held back.
Opportunities, by urgency and business impact
Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.
-
Disconnected Neural Data Ecosystems
Laboratory equipment operates in isolation with data trapped in local instrument memory, requiring manual transcription into spreadsheets or LIMS. Analysts waste up to 50% of their time searching for fragmented, inaccurate data, making real-time oversight impossible.
Implement unified middleware layer (Industrial Data Platform) connecting neuron-on-chip platform directly to SAP and LIMS through vendor-agnostic protocols like OPC UA, enabling "Source-to-Scientist" data work with 100% automated data capture.
-
Operational Blind Spots in Legacy Equipment
Legacy lab equipment lacks sensors or digital interfaces for real-time data streaming, creating "dark data" pockets where environmental conditions of the neuron-on-chip cannot be monitored automatically, necessitating error-prone manual records.
Retrofit legacy chillers, incubators, and bioreactors with IoT gateways (control board®) to digitize analog signals and extract data from legacy PLCs, integrating RS-232 and Profibus interfaces into cloud platforms without equipment replacement.
-
Biological Scale-up Variability
Scaling from R&D to high-throughput production introduces significant failure risk due to neuron sensitivity to micro-environmental changes. Manual lab methods are too slow to stabilize industrial-scale throughput, and failed experiments consume critical financial runway.
Develop Bioprocess Digital Twins and AI-based Vision Systems (YOLOv8) for real-time monitoring of cell states and foam detection, enabling simulation of parameters to predict batch outcomes and reduce expensive wet-lab failures.
-
Workforce Skills Gap and Technology Adoption
57% of laboratory staff lack technical knowledge to manage sophisticated bio-digital software, creating "Black Box Anxiety" where operators keep systems in manual mode, increasing frequency of data entry errors and limiting utilization of automation capabilities.
Deploy AR/VR immersive training modules and human-centric HMIs to bridge skills gap, creating "Sandbox" environments for safe practice and UX-driven redesigns to make automation transparent, transforming digital skepticism into fluency.
-
Regulatory Data Integrity Risk
Paper-based records and fragmented data capture create high risk of ALCOA+ violations and audit failures. Manual processes lead to "clock-stops" in FDA/EFSA evaluations, with 47% of regulatory delays lost to data requests and verification issues.
Implement Laboratory Execution System (LES) with automated GxP-compliant data capture, real-time verification of analyst training and instrument calibration, and immutable electronic audit trails ensuring 24/7 audit readiness.
What we'd propose
- Enterprise AI
Industrial Data Platform & IT/OT Integration
A unified middleware layer connecting legacy and modern lab equipment with central ERP, LIMS, and SAP systems to ensure a "Single Source of Truth" and eliminate manual data entry across neural signal acquisition workflows.
-
Ontology layer
DETAIL
-
Predictive models
DETAIL
-
Decision surfaces
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital Lab
Bioprocess Digital Twin & Simulation Platform
Cloud-agnostic digital twin development enabling predictive optimization and simulation of neuron-on-chip bioprocesses before physical execution to reduce wet-lab failures and accelerate clinical translation timelines.
-
Unified data backbone
DETAIL
-
Paperless workflows
DETAIL
-
Continuous QC release
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital CDMO
MTP-Based Modular Production Platform
Implementation of Module Type Package (MTP) standards (VDI/VDE/NAMUR 2658) providing a "universal driver" layer for equipment interoperability and "plug-and-produce" modularity enabling rapid scale-up without vendor lock-in.
-
OT/IT convergence
DETAIL
-
Batch intelligence
DETAIL
-
Production release flow
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital Lab
Immersive VR/AR Training & Human-Centric UX
Development of virtual production environment replicas and intuitive user interfaces to bridge the workforce skills gap, accelerate technical staff onboarding, and eliminate "Black Box Anxiety" through transparent automation design.
-
Unified data backbone
DETAIL
-
Paperless workflows
DETAIL
-
Continuous QC release
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital Lab
GxP Compliance & Laboratory Execution System
Implementation of a comprehensive Laboratory Execution System (LES) orchestrating people, instruments, and IT systems to ensure 21 CFR Part 11 compliance, ALCOA+ data integrity, and continuous regulatory audit readiness.
-
Unified data backbone
DETAIL
-
Paperless workflows
DETAIL
-
Continuous QC release
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
Digital maturity: today and target
Scored out of 100 across six dimensions. The target is what PlusTen Intelligence's own published ambition implies — not a perfect score.
- Asset Connectivity 35 → 95
- Standard lab equipment is often air-gapped or legacy (RS-232/Profibus); the target is retrofitting it for real-time cloud streaming.
- Data Unity & Integration 20 → 90
- Current "data islands" and fragmented IT/OT systems lead to manual entry and Excel workarounds; target is unified namespace with zero silos connecting neural chip to SAP/LIMS.
- Process Intelligence 30 → 85
- High scale-up variability and biological unpredictability in pilot-to-industrial transition; target is Digital Twins and AI Vision (YOLOv8) for predictive optimization.
- Workforce Readiness 43 → 90
- Documented 57% skills gap and general "Digital Hesitancy" or "Black Box Anxiety"; target is digital-native workforce empowered by AR/VR training and intuitive HMI.
- Regulatory Alignment 40 → 100
- Fragmented data and manual records risk "clock-stops" in FDA/EFSA approvals and violate ALCOA+ principles; target is 24/7 audit readiness with 100% automated GxP-compliant capture.
- Modular Scalability 15 → 95
- Current pilot-scale laboratory hindered by vendor-specific drivers and rigid infrastructure; target is "Plug & Produce" modularity via MTP standards for rapid reconfiguration.
Check this yourself
Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.
-
Self-assessment
Data & AI Maturity
See how ready your data actually is for the AI work you're planning.
-
Self-assessment
Find Your LIMS
Answer a few questions about your lab and get a shortlist of LIMS that fit it.
-
Market comparison
Pharma Data Platform Use Cases — Ranked
Use cases ranked by how hard they are against what they're worth.
-
Market comparison
Digital Lab: Equipment & Integration Map
Which lab instruments connect to which systems, and where the gaps usually are.
Think we've read this right?
Talk to usRelated reading
-
Still biotech or already techbio?
The results of a Tech Imperatives for biotech 2022 report indicate changes in biotech production and management.
-
Lab of Tomorrow: We’re at a Turning Point – Is Your Lab on the Right Track?
Do you know what the biggest paradox is? Biotech and pharma fully understand that digitization is the future. Most of them know that effective market competition is simply not possible without artificial intelligence, automation, and data analysis. And yet, many labs are still stuck in the past, working in isolation, manually analyzing data, and losing the potential that technology offers.
-
From Paper to Performance: Operational Efficiency and Compliance in Labs
Transform your QC lab with scalable digital solutions that embed compliance, boost efficiency, and deliver a future-ready competitive edge.
-
Accelerating lab and manufacturing operations with MTP – a modular approach
Among the various modular and plug-n-produce approaches, the Modular Type Package (MTP) approach has emerged as a game-changer.
-
Digital Twin Maturity Model – self-assessment tool
Initially, defining what a digital twin even is seemed simple - we have a real product and its virtual counterpart, and we combine the two.
This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with PlusTen Intelligence, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].